[1] Ansaldi F,Orsi A,Sticchi L,et al.Hepatitis C virus in the new era: Perspectives in epidemiology,prevention,diagnostics and predictors of response to therapy[J].World J Gastroenterol,2014,20(29):9633-9652.[2] 中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华肝脏病杂志,2004,12(4):194-198.[3] 赵 辉,谢 尧,李明慧.慢性丙型肝炎患者的血清HCV基因型和RNA含量与ALT和AST水平不相关[J].中华检验医学杂志,2007,30(6):631-634.[4] Mauss S,Hueppe D,John C, et al.Estimating the likelihood of sustained virological response in chronic hepatitis C therapy[J].J Viral Hepat,2011,18(4):e81-e90.[5] MarcianoS,Borzi SM,Dirchwolf M,et al.Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3[J].World J Hepatol,2015,7(4): 703-709.[6] Kainuma M,Furusyo N, Azuma K,etal.Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase[J].Hepatol Res,2012,42(1): 33-41.[7] Hiramatsu N,Inoue Y,Oze T,etal.Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study[J].J Gastroenterol,2011,46(11): 1335-1343.[8] Tohra SK,Taneja S,Ghosh S,et al.Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C[J].Dig Dis Sci,2011,56(8):2449-2455.[9] Zuberi BF,Zuberi FF,Memon SA,et al.Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population[J].World J Gastroenterol,2008,14(14):2218-2221.[10] Liu CH,Liu CJ,Lin CL, et al.Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter,randomized controlled trial[J].Clin Infect Dis,2008,47(10):1260-1269.[11] 方超萍,张薇薇,孙小波,等.丙型肝炎患者不同病毒载量与病毒学应答及肝功能改变的相关性[J].现代检验医学杂志,2012,27(5):18-21[12] Strader DB,Wright T,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C[J].Hepatology,2004,39(4):1147-1171.[13] 黄毛山,王秋英,方玉才,等.379例HCV感染者丙型肝炎病毒载量与抗HCV及肝功能指标的相关性分析[J].中华实验和临床病毒学杂志,2014,28(4):291-293.[14] 王 盟,郑伟阳,张红宇,等.聚乙二醇干扰素α-2a与干扰素α-2a治疗慢性丙型肝炎的短期疗效分析[J].中华肝脏病杂志,2014,22(4):255-259.[15] Gidding HF,Law MG,Amin J, et al.Hepatitis C treatment outcomes in Australian clinics[J].Med J Australia,2012,196(10):633-637.[16] Turbide C,Soulellis C,Deschenes M,et al.Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response[J].Can J Gastroenterol,2008,22(2):149-152[17] Mohamed AA,Amin MA,Ragab MM,et al.Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients[J].J Adv Res,2014,5(1): 117-123.[18] 于国英,黄 群,马玉秀.慢性丙型肝炎抗病毒治疗进展[J].临床肝胆病杂志,2015,31(4):626-629.[19] 张丹丹,叶佩燕,黄玉仙,等.慢性丙型肝炎患者获得快速病毒学应答的预测因素分析[J].临床肝胆病杂志,2014,30(12):1310-1314. |